(Journal Article): Will C-Peptide Substitution Make a Difference in Combating Complications in Insulin-Deficient Diabetes?
 
Sima AAF (Departments of Pathology and Neurology, Wayne State University, 540 E. Canfield Avenue, Detroit, MI 48201, USA, asima(at)med.wayne.edu )
 
IN: Rev Diabetic Stud 2004; 1(2):55-57
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: Not available.

TYPE OF PUBLICATION: Editorial

REFERENCES:

1. Steiner DF. The proinsulin C-peptide - a multirole molecule. Exp Diab Res 2004. 5:7-14. [DOD]
2. Sima AAF (ed). Physiological and pathophysiological significance of C-peptide actions. Exp Diab Res 2004. 5:1-96. [DOD]
3. Wahren J, Ekberg K, Johansson J, Henriksson M, Pramanik A, Johansson B-L, Rigler R, Jörnvall H. Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 2000. 278:E759-E768. [DOD]
4. Grunberger G, Qiang X, Li Z-G, Mathews ST, Sbriessa D, Shisheva A, Sima AAF. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 2001. 44:1247-1257. [DOD]
5. Jensen ME, Messina EJ. C-peptide induces a concentration-dependent dilatation of skeletal muscle arterioles only in the presence of insulin. Am J Physiol 1999. 276:H1223-H1228. [DOD]
6. Kitamura T, Kimura K, Makondo K, Furuya DT, Suzuki M, Yoshida T, Saito M. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein kinase dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 2003. 46:1698-1705. [DOD]
7. Greene DA, Lattimer SA and Sima AAF. Sorbitol, phosphoinositides and sodium-potassium ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987. 316:599-606. [DOD]
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001. 414:813-820. [DOD]
9. Sima AAF, Nathaniel V, Bril V, McEwen TAJ and Greene DA. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demon-stration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 1988. 81:349-364. [DOD]
10. Sima AAF. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003. 60:2445-2464. [DOD]
11. Forst T, De La Tour DD, Kunt T, Pfutzner A, Goitom K, Pohlmann T, Schneider S, Johansson BL, Wahren J, Lo-big M, et al. Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+/K+-ATPase activity in diabetes mellitus type 1. Clin Sci 2000. 98:283-290. [DOD]
12. Li Z-G, Zhang W, Sima AAF. C-peptide enhances insulin-mediated cell growth and protection against high glucose induced apoptosis in SH-SY5Y cells. Diab Metab Res Rev 2003. 19:375-385. [DOD]
13. Pierson CR, Zhang W, Sima AAF. Proinsulin C-peptide replacement in type 1 diabetic BB/Wor-rats prevents deficits in nerve fiber regeneration. J Neuropath Exp Neurology 2003. 62:765-779. [DOD]
14. Sima AAF, Zhang W, Li Z-G, Murakawa Y, Pierson CR. Molecular alterations underlie nodal and paranodal degenera-tion in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes 2004. 53:1556-1563. [DOD]
15. Johansson B-L, Linde B, Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia 1992. 35:1151-1158. [DOD]
16. Forst T, Kunt T, Pohlmann T, Goitom K, Engelbach M, Beyer J, Pfutzner A. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 1998. 101:2036-2041. [DOD]
17. Johansson B-L, Borg K, Fernquist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabetes Med 2000. 17:181-189. [DOD]
18. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindström P, Wahren J. Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 2003. 52:536-541. [DOD]
19. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993. 329:977-986. [DOD]
20. Zhang W, Yorek M, Pierson CR, Murakawa Y, Breidenbach A, Sima AAF. Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Internatl J Exp Diab Res 2001. 2(3):187-194. [DOD]
21. Vague P, Coste TC, Jannot MF, Raccah D, Tsimaratos M. C-peptide, Na+/K+-ATPase and diabetes. Exp Diab Res 2001. 24:1187-1191.
22. Forst T, Kunt T. Effects of C-peptide on microvascular blood flow and blood hemorheology. Exp Diab Res 2004. 5:51-64. [DOD]
23. Li Z-G, Zhang W, Sima AAF. C-peptide prevents hippocampal apoptosis in type 1 diabetes. Internatl J Exp Diab Res 2002. 3:241-246. [DOD]
24. Sima AAF, Kamiya H. The changing view of diabetic neuropathy. Science Med (in press). [DOD]
25. Li H, Xu L, Dunbar JC, Dhabuwala CB, Sima AAF. Effects of C-peptide on expression of endothelial NOS (eNOS) and inducible NOS (iNOS) in human cavernosal smooth muscle cell. J Urol (in press). [DOD]
26. Stevens MJ, Zhang W, Li F, Sima AAF. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor-rats. Am J Physiol (in press). [DOD]